CN Patent

CN115461072A — 用于治疗非酒精性脂肪性肝炎的司美格鲁肽

Assigned to Novo Nordisk AS · Expires 2022-12-09 · 3y expired

What this patent protects

本发明涉及GLP‑1受体激动剂司美格鲁肽在用于治疗非酒精性脂肪性肝炎的药物疗法中的用途。

USPTO Abstract

本发明涉及GLP‑1受体激动剂司美格鲁肽在用于治疗非酒精性脂肪性肝炎的药物疗法中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN115461072A
Jurisdiction
CN
Classification
—
Expires
2022-12-09
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.